knowledge -WSS

knowledge

author：focus 2025-10-02 18:48:36 - browse：251

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Researchers test human milk's ability to repair gut microbiome

knowledge

WSS

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

How are insurers handling Leqembi and related scans?

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

After half a century, Israel moves to evict squatter from his cave home on the beach

Gut bacteria may contribute to kidney autoimmunity, study finds

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

As demand for Covid shots wanes, Moderna seeks its next success

Britney Spears to release memoir, 'The Woman In Me,' later this year

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Hundreds died while taking an arthritis drug, but nobody alerted patients

Anesthesiologist group: stop taking Ozempic before surgery

Britney Spears to release memoir, 'The Woman In Me,' later this year

DIEP, the 'gold standard' of breast reconstruction, is under threat

Study: Black kids more likely to die after surgery than white kids

entertainment

Britney Spears to release memoir, 'The Woman In Me,' later this year

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Scientific mystery highlights the blind spots in genomics databases

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

People with mental disorders often marry others with same

Study: Black kids more likely to die after surgery than white kids

focus

knowledge

focus

entertainment